出境医 / 权威医院
国家：
科室：
国外推荐医生 更多
Gregory Aaen MD
经验：11-20年
Brian Aalbers DO
经验：11-20年
Oran Aaronson MD
经验：11-20年
Glen Scott DO
经验：21年以上
Cecile Becker MD
经验：11-20年
浦上克哉 教授
经验：21年以上
岩田淳 准教授
经验：21年以上
阿保義久
经验：21年以上
林明人 教授
经验：21年以上
野元正弘
经验：21年以上
国外治疗案例 更多
国外临床试验 更多
- A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT (COSI)
- PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia
- BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients
- A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
- Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease
- Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia
- Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
- A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS
- Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms
- CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients
「注：国外医院医院排名数据引用于美国世界新闻播报及日本病院情报局，请周知」